Chronic hepatitis B is a long-term viral infection that affects millions of people worldwide. Patients usually require lifelong antiviral treatment to control the virus and prevent liver damage.
Some older antiviral medications, such as lamivudine, can lead to the development of viral resistance. This means the virus changes in a way that makes certain treatments less effective. Even though newer drugs like entecavir are stronger and more resistant to these changes, previous exposure to lamivudine may increase the risk of developing additional resistance mutations.
By analyzing viral genetic material from blood samples using advanced sequencing technology, this research will help improve understanding of antiviral resistance patterns in patients with chronic hepatitis B in Turkey and may support better treatment decisions in the future.
Age ≥18 years
HBsAg positive
Group 1: Either treatment-naïve participants with HBV DNA>2000 IU/ml
Group 2: Prior lamivudine therapy ≥6 months with switch to ADVor TDF or TAF
Prior entecavir exposure
Prior telbivudine exposure
Age <18 years
Inability to provide informed consent Note: Previous adefovir or (pegylated) interferon use is not an exclusion criterion.
Yaşar Bayındır, MD
Lead sponsor
Guven Health Group
Sponsor institution
SOUTHEAST NEUROLOGY AND INFECTIOUS DISEASES SOCIETY
Collaborator